The effectiveness of combined treatment with Opicapone and other anti-Parkinson drugs

Opicapone is a new peripheral reversible catechol-O-methyltransferase (COMT) inhibitor, which is used as an adjuvant treatment for patients with Parkinson's disease, especially those with levodopa "switching phenomenon" or motor fluctuations. Its main function is to prolong the half-life of levodopa in the blood and increase central dopamine levels, thereby improving motor symptoms. Opicapone is often used in combination with levodopa/carbidopa and may act synergistically with other dopamine agonists or MAO-B inhibitors.

Clinical studies have shown that the combined use of opicapone and levodopa/carbidopa can significantly extend the "on" time and reduce the "off" time. Patients experienced improvements in daytime mobility, gait stability, and tremor control. Compared with the use of levodopa alone, the combination of opicapone can reduce the fluctuation range of motor symptoms and improve the quality of life without increasing the risk of serious side effects related to levodopa.

Opicapone can also be used in combination with dopamine receptor agonists (such as pramipexole) or MAO-B inhibitors (such as rasagiline). Studies have shown that this type of combination therapy can maintain efficacy while reducing the dose of levodopa, and reduce the motor complications caused by long-term high-dose levodopa, such as dyskinesia. The combined regimen was excellent in reducing movement fluctuations, prolonging effective medication time, and improving daily activities.

In clinical practice, the combined use of opicapone requires individualized dose adjustment. Especially when used simultaneously with levodopa, MAO-B inhibitors or dopamine agonists, blood pressure, mental status, and liver and kidney function need to be monitored. Patients should take medications regularly as directed by their doctor and cooperate with regular follow-up visits to evaluate efficacy and tolerance. Through scientific combination of drugs, Opicapone can significantly improve the motor symptoms and quality of life of patients with Parkinson's disease, while reducing the risk of side effects of high-dose single drugs.

Reference materials:https://www.drugs.com/